Connect to share and comment

French antitrust body probes Roche, Novartis over eye treatment

PARIS/ZURICH (Reuters) - France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in respect of eye disease treatment, the companies said on Thursday. A statement on the authority's website said it had conducted "search and confiscation" operations on April 8 in relation to treatment for wet age-related macular degeneration (AMD), but it did not name the companies involved.

India drugs giant rejects Novartis patent accusations

Leading Indian drug company Biocon on Friday rejected allegations by Novartis that it infringed on the Swiss pharmaceutical giant's patent for its blockbuster diabetes drug Galvus. Novartis announced Thursday it was seeking an injunction in the Delhi High Court to stop Biocon from launching a generic version of Galvus, also known as Vildagliptin. The suit against Biocon is the latest legal salvo in a campaign by global drugmakers against the nation's huge copycat drugs industry that the pharmaceutical companies say reduces incentives to produce cutting-edge medicines.

India drugs giant rejects Novartis patent accusations

Leading Indian drug company Biocon on Friday rejected allegations by Novartis that it infringed on the Swiss pharmaceutical giant's patent for its blockbuster diabetes drug Galvus. Novartis announced Thursday it was seeking an injunction in the Delhi High Court to stop Biocon from launching a generic version of Galvus, also known as Vildagliptin.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Novartis replaces top Japan executives over drug trial scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, told a news briefing in Tokyo that the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". kh-oh-pb/dan

Novartis says lung cancer patients respond to drug in study

ZURICH (Reuters) - Novartis said late on Wednesday that a majority of patients given a development drug against non-small cell lung cancer had responded to the treatment, according to study results published in the New England Journal of Medicine. The Basel-based drugmaker's LDK378 has been declared a "breakthrough therapy", a designation created by the U.S. Food and Drug Administration in 2012 to help speed drugs to market that treat serious or life-threatening conditions and are deemed likely to work better than existing treatments.

Novartis CEO reshapes drugmaker for 'brutal' new world

By Caroline Copley and Ben Hirschler BASEL, Switzerland (Reuters) - Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending. At least one of the three sub-scale units - animal health, vaccines and over-the-counter medicines - is not expected to make the cut, he told Reuters in the clearest indication yet of how the review is progressing.

Novartis chairman rules out merger with Roche: paper

ZURICH (Reuters) - Swiss pharma group Novartis <NOVN.VX> will work more closely with rival Roche <ROG.VX> but rules out a merger, its chairman said in a newspaper interview on Sunday. Asked whether the two companies wanted to stay independent, Joerg Reinhardt, who took over as Novartis chairman in August, told Swiss newspaper SonntagsZeitung: "Absolutely." He said, however, that he'd met outgoing Roche Chairman Franz Humer a few weeks ago and was also exchanging emails with his successor Christoph Franz.

Japan prosecutors raid Novartis over drug ad scandal

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said. Officials from the Tokyo Prosecution Office were searching the headquarters of Novartis Pharma KK in central Tokyo, public broadcaster NHK and other media reported.
Syndicate content